Can multiple myeloma become a curable disease?
作者信息
San-Miguel Jesús F, Mateos María-Victoria
出版信息
Haematologica. 2011 Sep;96(9):1246-8. doi: 10.3324/haematol.2011.051169.
Abstract
摘要
相似文献
1
Can multiple myeloma become a curable disease?多发性骨髓瘤能成为一种可治愈的疾病吗？
Haematologica. 2011 Sep;96(9):1246-8. doi: 10.3324/haematol.2011.051169.
2
3
Intravenous pamidronate for myeloma bone disease: can the dose be lowered?静脉注射帕米膦酸治疗骨髓瘤骨病：剂量可以降低吗？
Lancet Oncol. 2010 Oct;11(10):913-4. doi: 10.1016/S1470-2045(10)70227-8.
4
Multiple myeloma.多发性骨髓瘤
Hematol Oncol Clin North Am. 2014 Oct;28(5):xi-xii. doi: 10.1016/j.hoc.2014.08.001.
5
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.来那度胺与大剂量美法仑联合自体干细胞移植治疗复发性骨髓瘤的I/II期试验
Leukemia. 2015 Sep;29(9):1945-8. doi: 10.1038/leu.2015.54. Epub 2015 Feb 27.
6
The current landscape of multiple myeloma treatment.多发性骨髓瘤的当前治疗格局。
Leuk Res. 2008 Dec;32 Suppl 1:S1-24. doi: 10.1016/S0145-2126(08)70002-X.
7
[Multiple myeloma].[多发性骨髓瘤]
Rinsho Ketsueki. 2014 Feb;55(2):201-12.
8
The role of autologous stem cell transplantation in the management of multiple myeloma.自体干细胞移植在多发性骨髓瘤治疗中的作用。
Pathol Biol (Paris). 1999 Feb;47(2):199-202.
9
Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?老年多发性骨髓瘤患者的自体移植：我们提出的问题正确吗？
Bone Marrow Transplant. 2006 Nov;38(9):585-92. doi: 10.1038/sj.bmt.1705486. Epub 2006 Sep 4.
10
The treatment of elderly patients with multiple myeloma: is more better?
Oncology (Williston Park). 2010 Oct;24(11):1004, 1006.
引用本文的文献
1
Proteasome and PARP1 dual-target inhibitor for multiple myeloma: Fluzoparib.用于多发性骨髓瘤的蛋白酶体和PARP1双靶点抑制剂：氟唑帕利。
Biochem Biophys Rep. 2024 Jul 7;39:101781. doi: 10.1016/j.bbrep.2024.101781. eCollection 2024 Sep.
2
Consolidation and maintenance therapy with bortezomib for Vietnamese patients with multiple myeloma after autologous transplantation.硼替佐米对越南多发性骨髓瘤患者自体移植后的巩固和维持治疗
Leuk Res Rep. 2023 Mar 21;19:100368. doi: 10.1016/j.lrr.2023.100368. eCollection 2023.
3
Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma.自噬：一种应对多发性骨髓瘤药物耐药性的潜在治疗靶点。
Int J Mol Sci. 2023 Mar 23;24(7):6019. doi: 10.3390/ijms24076019.
4
An nusual ocular manifestation of multiple myeloma.多发性骨髓瘤的一种不常见眼部表现。
BMJ Case Rep. 2022 Jul 22;15(7):e247863. doi: 10.1136/bcr-2021-247863.
5
Multiple myeloma with presentation in the oral cavity.口腔表现的多发性骨髓瘤。
J Oral Maxillofac Pathol. 2022 Jan-Mar;26(1):104-107. doi: 10.4103/jomfp.jomfp_377_21. Epub 2022 Mar 31.
6
Smoldering multiple myeloma: Reviewing the rationale for intervention.冒烟型多发性骨髓瘤：干预策略的探讨。
Leuk Lymphoma. 2022 Sep;63(9):2033-2040. doi: 10.1080/10428194.2022.2068008. Epub 2022 May 9.
7
Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.1q21 增益在多发性骨髓瘤中的预测价值强烈依赖于并发的细胞遗传学异常和一线治疗。
Am J Cancer Res. 2021 Sep 15;11(9):4438-4454. eCollection 2021.
8
Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group.骨髓微环境相互作用与多发性骨髓瘤的当前临床实践：巴尔干骨髓瘤研究组综述
J Clin Med. 2021 Aug 31;10(17):3940. doi: 10.3390/jcm10173940.
9
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). Venetoclax 联合达雷妥尤单抗和地塞米松，加或不加硼替佐米，治疗伴有和不伴有 t(11;14)的复发/难治性多发性骨髓瘤的 I 期研究。
J Clin Oncol. 2021 Nov 10;39(32):3602-3612. doi: 10.1200/JCO.21.00443. Epub 2021 Aug 13.
10
Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management.基于血液的癌前和有症状浆细胞肿瘤风险分层以改善患者管理。
Am J Cancer Res. 2021 Jun 15;11(6):2736-2753. eCollection 2021.
本文引用的文献
1
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.干细胞移植后多发性骨髓瘤反应的长期预后意义。
Blood. 2011 Jul 21;118(3):529-34. doi: 10.1182/blood-2011-01-332320. Epub 2011 Apr 11.
2
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.硼替佐米联合沙利度胺和地塞米松与沙利度胺和地塞米松作为新诊断多发性骨髓瘤患者双自体干细胞移植前诱导治疗和巩固治疗的比较：一项随机 3 期研究。
Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9.
3
International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.国际骨髓瘤工作组关于异体干细胞移植治疗多发性骨髓瘤现状的共识声明。
J Clin Oncol. 2010 Oct 10;28(29):4521-30. doi: 10.1200/JCO.2010.29.7929. Epub 2010 Aug 9.
4
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.多发性骨髓瘤的总治疗 3 方案：VTD 维持成分（硼替佐米、沙利度胺和地塞米松）累积剂量和过早停药的预后意义，与治疗的所有阶段相关。
Blood. 2010 Aug 26;116(8):1220-7. doi: 10.1182/blood-2010-01-264333. Epub 2010 May 25.
5
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.硼替佐米、沙利度胺和地塞米松巩固治疗自体移植后骨髓瘤患者的主要肿瘤缩小和持续分子缓解。
J Clin Oncol. 2010 Apr 20;28(12):2077-84. doi: 10.1200/JCO.2009.23.7172. Epub 2010 Mar 22.
6
Hematopoietic stem cell transplantation for multiple myeloma beyond 2010.2010 年后多发性骨髓瘤的造血干细胞移植。
Blood. 2010 May 6;115(18):3655-63. doi: 10.1182/blood-2009-08-238196. Epub 2010 Mar 4.
7
Survival and years of life lost in different age cohorts of patients with multiple myeloma.不同年龄组多发性骨髓瘤患者的生存和寿命损失。
J Clin Oncol. 2010 Mar 20;28(9):1599-605. doi: 10.1200/JCO.2009.25.2114. Epub 2010 Feb 22.
8
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.在后续的 2006-66 试验中，使用 VRD 维持治疗，在基因表达谱定义的低危多发性骨髓瘤中，证实了 Total Therapy 3（2003-33）的优异疗效。
Blood. 2010 May 27;115(21):4168-73. doi: 10.1182/blood-2009-11-255620. Epub 2010 Feb 2.
9
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.自体移植治疗多发性骨髓瘤的长期随访：法国骨髓瘤协作组、西南肿瘤协作组和阿肯色大学医学科学中心进行的方案更新。
J Clin Oncol. 2010 Mar 1;28(7):1209-14. doi: 10.1200/JCO.2009.25.6081. Epub 2010 Jan 19.
10
How I treat multiple myeloma in younger patients.我是如何治疗年轻患者的多发性骨髓瘤。
Blood. 2009 Dec 24;114(27):5436-43. doi: 10.1182/blood-2009-07-204651. Epub 2009 Oct 27.
Zotero 插件